by 
Acute bacterial skin and skin structure infections are common bacterial infections that affect the skin and soft tissues. The infections are mainly caused by Staphylococcus aureus and Streptococcus pyogenes bacteria. These infections require prompt treatment with antibiotics to avoid complications. Some of the common symptoms of acute bacterial skin infections include pain, swelling, warmth, and redness at the site of infection. The increasing incidence of antibiotic resistance and limited treatment options have fueled the need for developing new and effective antibiotic therapies for treating such infections.
The global acute bacterial skin and skin structure infections market size is estimated to be valued at US$ 3,466.6 million in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period from 2023 to 2030.
Key Takeaways
Key players operating in the Acute Bacterial Skin and Skin Structure Infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.
The market provides significant opportunities for players as there exists a huge unmet need for developing new treatment options owing to rising antibiotic resistance. Players are focused on developing novel antibiotic therapies with new mechanisms of action.
There are ongoing advancements in antibiotic therapies including combination therapies and monoclonal antibodies to provide synergistic therapy and target specific disease-causing pathogens respectively.
Market Drivers
The key driver fueling the growth of the acute bacterial skin and skin structure infections market is the increasing prevalence of antibiotic-resistant strains. Long-term exposure to antibiotics has led to the development of resistance in bacterial strains against conventional drugs. This has enhanced the need for novel anti-infective therapies. Additionally, rising healthcare spending in emerging nations is also contributing to the market growth.
Current Challenges in Acute Bacterial Skin and Skin Structure Infections Market:
The acute bacterial skin and skin structure infections (ABSSSI) market faces several challenges. Firstly, the increasing antibiotic resistance among bacterial pathogens is a major concern. Many common bacteria that cause ABSSSI such as Staphylococcus aureus have developed resistance to front-line antibiotics. This has reduced treatment options and made ABSSSI more difficult to treat. Secondly, inaccurate diagnosis of bacterial infections continues to pose problems. Differentiating bacterial from viral or fungal infections based on symptoms alone can be challenging. This often leads to inappropriate initial treatment and delays. Thirdly, lack of new antibiotic drug development also restricts treatment options. Many large pharmaceutical companies have exited the antibiotic research and development space due to low commercial incentives. This has slowed the development of novel drugs needed to tackle rising drug resistance. Unless these challenges are addressed, managing ABSSSI could become more difficult in the coming years.
SWOT Analysis
Strength: Potential for combination therapies using existing antibiotics: Combining existing antibiotics with different mechanisms can restore their efficacy against resistant bacteria and widen treatment options.
Weakness: Under-diagnosis of infections: Distinguishing bacterial from other types remains problematic leading to incorrect initial treatment.
Opportunity: Developing rapid diagnostic tests: New tests that can quickly and accurately diagnose bacterial infections at point-of-care present opportunities to improve management.
Threats: Increasing antimicrobial resistance: Resistance is developing rapidly against front-line antibiotics used to treat ABSSSI, reducing treatment effectiveness over time.
Geographical Regions of Market Concentration:
North America currently accounts for the largest share of the global ABSSSI market in terms of value. This is attributed to rising incidence of infections, availability of advanced treatment options, and growing awareness about proper management of ABSSSI. The US dominates the North American market due to its large pharmaceutical industry and high healthcare spending. Europe is the second largest regional market boosted by growing resistance, guidelines promoting appropriate antibiotic use, and increasing R&D activities. Asia Pacific is expected to register fastest growth during forecast period supported by expanding medical facilities, growing populations, and increasing incidence of resistant bacterial infections.
Fastest Growing Geographical Region:
The Asia Pacific region is projected to be the fastest growing geographical market for ABSSSI during 2023-2030 forecast period. This is because countries like India and China have huge populations at risk of infections coupled with improving access to healthcare facilities. Rising disposable incomes also enhance patients’ ability to afford treatments. Additionally, growing awareness about benefits of managing infections properly and increasing collaborations between foreign drug makers and domestic players are aiding market growth. Rapid urbanization and changing lifestyles also contribute to rising incidence of bacterial infections in the region.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
